Лимфома из клеток мантии

1. Carbone PP et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971; 31 (11): 1860–1.
2. Демина Е.А. и др. Общие принципы диагностики лимфом. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 9–27.
[Demina E.A. et al. General principles of lymphoma diagnosis. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 9–27 (in Russian).]
3. Воробьев В.И., Тумян Г.С. Лимфома из клеток мантии. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 68–80.
[Vorobiev V.I., Tumyan G.S. Mantle cell lymphoma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 68–80 (in Russian).]
4. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
5. Dreyling M et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 4): iv62–iv71.
6. Gill S et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008; 8 (3): 159–65.
7. Howard OM et al. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 2002; 20 (5): 1288–94.
8. LaCasce AS et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119 (9): 2093–9.
9. Lenz G et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23 (9): 1984–92.
10. Bernstein SH et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24 (6): 1587–93.
11. Damon LE et al. Immunochemotherapy and autologous stem- cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27 (36): 6101–8.
12. Sun T et al. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol 2003; 74 (1): 78–84.
13. Alavi A et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11 (3): 261–6.
14. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. Swerdlow SH, Campo E, Harris NL et al. 2017.
15. Dreyling M et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105 (7): 2677–84.
16. Fenske TS, Carreras T, Zhang M. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation. Ann Oncol 2011; 22 (Suppl. 4): Abstract 018.
17. Visco C et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31 (11): 1442–9.
18. Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381 (9873): 1203–10.
19. Geisler CH. Front-line therapy of mantle cell lymphoma. Haematologica 2010; 95: 1241–3.
20. Kluin-Nelemans HC et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367 (6): 520–31.
21. Kahl BS et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17 (9): 1418–23.
22. Hilal T et al. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. Am J Hematol 2018; 93 (10): 1220–6.
23. Rule S et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 2017; 179 (3): 430–8.
24. Ruan J et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood 2018; 132 (19): 2016–25.
25. Romaguera JE et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150 (2): 200–8.
26. Martin P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27 (8): 1209–13.
27. Hermine O et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388 (10044): 565–75.
28. Merli F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156 (3): 346–53.
29. Chihara D et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 2016; 172 (1): 80–8.
30. Geisler CH et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur. Br J Haematol 2012; 158 (3): 355–62.
31. Eskelund CW et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175 (3): 410–18.
32. Pott C et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network. Blood 2010; 116 (21).
33. Le Gouill S et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017; 377 (13): 1250–60.
34. Hoster E, Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematol Am Soc Hematol Educ Progr 2016; 2016 (1): 437–45.
35. Cheminant M et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 2016; 101 (3): 336–45.
36. Gatt ME, Grisaro S. Central nervous system prophylaxis in mantle cell lymphoma. Blood 2009; 114 (26): 5402–3.
37. Crocchiolo R et al. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica 2015; 100 (10): e423–e427.
38. Dreyling M et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leuk Lymphoma 2018; 59 (8): 1814–28.
39. Weigert O et al. High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma. Blood 2006; 108 (11): 2449.
40. Gironella M et al. Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma. Blood 2012; 120 (21).
41. Corazzelli G et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: Results of a pilot study. Ann Oncol 2006; 17 (Suppl.): 4.
42. Corazzelli G et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64 (5): 907–16.
43. Friedberg JW et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117 (10): 2807–12.
44. Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369 (6): 507–16.
45. Wang ML et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood 2015; 126 (6): 739–45.
46. Dreyling M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet 2016; 387 (10020): 770–8.
47. Wang ML et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 2016; 17 (1): 48–56.
48. Trněný M et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet. Oncol. 2016; 17 (3): 319–31.
49. Chong EA et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. Clin Cancer Res 2015; 21 (8): 1835–42.
50. Le Gouill S et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter experience. Ann Oncol 2012; 23 (10): 2695–703.
51. Soubeyran P, Gressin R. Treatment of the elderly patient with mantle cell lymphoma. Hematology 2016; 2016 (1): 425–31.
52. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
53. Gressin R et al. Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. Blood. 2014; 124 (21): 148.
54. Robak T et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19 (11): 1449–58.
55. Spurgeon SE et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2011; 52 (8): 1488–94.
56. Kluin-Nelemans HC et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020; 38 (3): 248–56.
57. Robak T et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107 (7): 1542–50.
58. Coleman M et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008; 112 (10): 2228–32.
59. Владимирова Л.Ю. и др. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 502–11.
[Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol'nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).]
60. Барях Е.А., Мякова Н.В., Поддубная И.В. Профилактика и лечение синдрома лизиса опухоли. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; с. 251–3.
[Bariakh E.A., Miakova N.V., Poddubnaya I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoy, V.G. Savchenko. 2018; s. 251–3 (in Russian).]
61. Aapro M и др. Клинические рекомендации по лечению анемии у больных злокачественными новообразованиями. М.: Ассоциация онкологов России, 2014.
[Aapro M et al. Clinical guidelines for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).]
62. Орлова Р.В. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Практические рекомендации Российского общества клинической онкологии. Лекарственное лечение злокачественных опухолей. Поддерживающая терапия в онкологии. 2018; с. 494–501.
[Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; s. 494–501 (in Russian).]
63. Абузарова Г.Р. и др. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. М.: ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016.
[Abuzarova G.R. et al. Anesthesia for adults and children in the provision of medical care. Guidelines. Moscow: FGBOU IN RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).]
64. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных. Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. 2018; c. 278–88.
[Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoy, V.G. Savchenko. 2018; c. 278–88 (in Russian).]
65. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
66. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5; Suppl. 1): S88–94.
67. Hoster E et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111 (2): 558–65.
68. Schaffel R et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma. Ann Oncol 2010; 21 (1): 133–9.
69. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
70. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
71. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
72. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
73. Delarue R et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013; 121 (1): 48–53.
74. Geisler CH et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112 (7): 2687–93.
75. Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia 2014; 28 (11): 2117–30.
76. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

________________________________________________

1. Carbone PP et al. Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Res 1971; 31 (11): 1860–1.
2. Demina E.A. et al. General principles of lymphoma diagnosis. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 9–27 (in Russian).
3. Vorobiev V.I., Tumyan G.S. Mantle cell lymphoma. Russian clinical guidelines for the diagnosis and treatment of malignant lymphoproliferative diseases. Ed. I.V. Poddubnaya, V.G. Savchenko. 2018; p. 68–80 (in Russian).
4. Zelenetz AD et al. B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology. Version 5. 2019.
5. Dreyling M et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28 (Suppl. 4): iv62–iv71.
6. Gill S et al. [18F]Fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008; 8 (3): 159–65.
7. Howard OM et al. Rituximab and CHOP Induction Therapy for Newly Diagnosed Mantle-Cell Lymphoma: Molecular Complete Responses Are Not Predictive of Progression-Free Survival. J Clin Oncol 2002; 20 (5): 1288–94.
8. LaCasce AS et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119 (9): 2093–9.
9. Lenz G et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23 (9): 1984–92.
10. Bernstein SH et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24 (6): 1587–93.
11. Damon LE et al. Immunochemotherapy and autologous stem- cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27 (36): 6101–8.
12. Sun T et al. Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma. Am J Hematol 2003; 74 (1): 78–84.
13. Alavi A et al. Fluorodeoxyglucose-positron-emission tomography findings in mantle cell lymphoma. Clin Lymphoma Myeloma Leuk 2011; 11 (3): 261–6.
14. Swerdlow SH et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon, France: International Agency for Research in Cancer (IARC). Ed. Swerdlow SH, Campo E, Harris NL et al. 2017.
15. Dreyling M et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105 (7): 2677–84.
16. Fenske TS, Carreras T, Zhang M. Outcome of patients with mantle-cell lymphoma undergoing autologous versus reduced-intensity allogenic transplantation. Ann Oncol 2011; 22 (Suppl. 4): Abstract 018.
17. Visco C et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31 (11): 1442–9.
18. Rummel MJ et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381 (9873): 1203–10.
19. Geisler CH. Front-line therapy of mantle cell lymphoma. Haematologica 2010; 95: 1241–3.
20. Kluin-Nelemans HC et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367 (6): 520–31.
21. Kahl BS et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: A pilot study from the Wisconsin Oncology Network. Ann Oncol 2006; 17 (9): 1418–23.
22. Hilal T et al. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. Am J Hematol 2018; 93 (10): 1220–6.
23. Rule S et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol 2017; 179 (3): 430–8.
24. Ruan J et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood 2018; 132 (19): 2016–25.
25. Romaguera JE et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150 (2): 200–8.
26. Martin P et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27 (8): 1209–13.
27. Hermine O et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388 (10044): 565–75.
28. Merli F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156 (3): 346–53.
29. Chihara D et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 2016; 172 (1): 80–8.
30. Geisler CH et al. Nordic MCL2 trial update: Six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur. Br J Haematol 2012; 158 (3): 355–62.
31. Eskelund CW et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175 (3): 410–18.
32. Pott C et al. R-CHOP/R-DHAP Compared to R-CHOP Induction Followed by High Dose Therapy with Autologous Stem Cell Transplantation Induces Higher Rates of Molecular Remission In MCL: Results of the MCL Younger Intergroup Trial of the European MCL Network. Blood 2010; 116 (21).
33. Le Gouill S et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med 2017; 377 (13): 1250–60.
34. Hoster E, Pott C. Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment. Hematol Am Soc Hematol Educ Progr 2016; 2016 (1): 437–45.
35. Cheminant M et al. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 2016; 101 (3): 336–45.
36. Gatt ME, Grisaro S. Central nervous system prophylaxis in mantle cell lymphoma. Blood 2009; 114 (26): 5402–3.
37. Crocchiolo R et al. Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. Haematologica 2015; 100 (10): e423–e427.
38. Dreyling M et al. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. Leuk Lymphoma 2018; 59 (8): 1814–28.
39. Weigert O et al. High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma. Blood 2006; 108 (11): 2449.
40. Gironella M et al. Rituximab Plus Gemcitabine and Oxaliplatin As Salvage Therapy in Patients with Relapsed/Refractory Mantle-Cell Lymphoma. Blood 2012; 120 (21).
41. Corazzelli G et al. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin’s lymphoma: Results of a pilot study. Ann Oncol 2006; 17 (Suppl.): 4.
42. Corazzelli G et al. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma. Cancer Chemother Pharmacol 2009; 64 (5): 907–16.
43. Friedberg JW et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117 (10): 2807–12.
44. Wang ML et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369 (6): 507–16.
45. Wang ML et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: Updated safety and efficacy results. Blood 2015; 126 (6): 739–45.
46. Dreyling M et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: An international, randomised, open-label, phase 3 study. Lancet 2016; 387 (10020): 770–8.
47. Wang ML et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol 2016; 17 (1): 48–56.
48. Trněný M et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet. Oncol. 2016; 17 (3): 319–31.
49. Chong EA et al. Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. Clin Cancer Res 2015; 21 (8): 1835–42.
50. Le Gouill S et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: A multicenter experience. Ann Oncol 2012; 23 (10): 2695–703.
51. Soubeyran P, Gressin R. Treatment of the elderly patient with mantle cell lymphoma. Hematology 2016; 2016 (1): 425–31.
52. Flinn IW et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123 (19): 2944–52.
53. Gressin R et al. Frontline Therapy with the Ribvd Regimen Elicits High Clinical and Molecular Response Rates and Long PFS in Elderly Patients Mantle Cell Lymphoma (MCL); Final Results of a Prospective Phase II Trial By the Lysa Group. Blood. 2014; 124 (21): 148.
54. Robak T et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19 (11): 1449–58.
55. Spurgeon SE et al. Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma. Leuk Lymphoma 2011; 52 (8): 1488–94.
56. Kluin-Nelemans HC et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020; 38 (3): 248–56.
57. Robak T et al. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer 2006; 107 (7): 1542–50.
58. Coleman M et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008; 112 (10): 2228–32.
59. Vladimirova L.Iu. et al. Prakticheskie rekomendatsii po profilaktike i lecheniiu toshnoty i rvoty u onkologicheskikh bol'nykh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; p. 502–11 (in Russian).
60. Bariakh E.A., Miakova N.V., Poddubnaya I.V. Profilaktika i lechenie sindroma lizisa opukholi. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoy, V.G. Savchenko. 2018; s. 251–3 (in Russian).
61. Aapro M et al. Clinical guidelines for the treatment of anemia in patients with malignant neoplasms. Moscow: Association of Oncologists of Russia, 2014 (in Russian).
62. Orlova R.V. et al. Prakticheskie rekomendatsii po lecheniiu anemii pri zlokachestvennykh novoobrazovaniiakh. Prakticheskie rekomendatsii Rossiiskogo obshchestva klinicheskoi onkologii. Lekarstvennoe lechenie zlokachestvennykh opukholei. Podderzhivaiushchaia terapiia v onkologii. 2018; s. 494–501 (in Russian).
63. Abuzarova G.R. et al. Anesthesia for adults and children in the provision of medical care. Guidelines. Moscow: FGBOU IN RNIMU im. N.I. Pirogova Minzdrava Rossii, 2016 (in Russian).
64. Abuzarova G.R. Lechenie bolevogo sindroma u onkologicheskikh bol'nykh. Rossiiskie klinicheskie rekomendatsii po diagnostike i lecheniiu zlokachestvennykh limfoproliferativnykh zabolevanii. Pod red. I.V. Poddubnoy, V.G. Savchenko. 2018; c. 278–88 (in Russian).
65. Cheson BD et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (5): 579–86.
66. Paul KL. Rehabilitation and exercise considerations in hematologic malignancies. Am J Phys Med Rehabil 2011; 90 (5; Suppl. 1): S88–94.
67. Hoster E et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111 (2): 558–65.
68. Schaffel R et al. Prognostic impact of proliferative index determined by quantitative image analysis and the international prognostic index in patients with mantle cell lymphoma. Ann Oncol 2010; 21 (1): 133–9.
69. Yelvington BJ. Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma. J Adv Pract Oncol 2018; 9 (5): 530–4.
70. Davies A et al. Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. Adv Ther 2017; 34 (10): 2210–31.
71. García‐Muñoz R et al. Safety of switching from intravenous to subcutaneous rituximab during first‐line treatment of patients with non‐Hodgkin lymphoma: the Spanish population of the MabRella study. Br J Haematol 2020; 188 (5): 661–73.
72. Macdonald D et al. A canadian perspective on the subcutaneous administration of rituximab in non-Hodgkin lymphoma. Curr Oncol 2017; 24 (1): 33–9.
73. Delarue R et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013; 121 (1): 48–53.
74. Geisler CH et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112 (7): 2687–93.
75. Dreyling M, Ferrero S, Hermine O. How to manage mantle cell lymphoma. Leukemia 2014; 28 (11): 2117–30.
76. Oken MM et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5 (6): 649–55.

В.И. Воробьев1, Г.С. Тумян2,3, Н.А. Фалалеева4, В.В. Птушкин1, Е.А. Османов3,5, И.В. Поддубная2, В.В. Байков6, А.М. Ковригина7,8, А.А. Невольских4, С.А. Иванов4, Ж.В. Хайлова4, Т.Г. Геворкян3

1 ГБУЗ «Городская клиническая больница им. С.П. Боткина» Департамента здравоохранения г. Москвы, Москва, Россия;
2 ФГАОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия;
3 ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России, Москва, Россия;
4 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Научный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
5 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
6 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» 
Минздрава России, Санкт-Петербург, Россия;
7 Академия постдипломного образования ФМБА России, Москва, Россия;
8 ФГБУ «Национальный медицинский исследовательский центр гематологии» Минздрава России, Москва, Россия

________________________________________________

Vladimir I. Vorob'ev1, Gaiane S. Tumian2,3, Natalia A. Falaleeva4, Vadim V. Ptushkin1, Evgenii A. Osmanov3,5, Irina V. Poddubnaya2, Vadim V. Baikov6, Alla M. Kovrigina7,8, Aleksei A. Nevol'skikh4, Sergei A. Ivanov4, Zhanna V. Khailova4, Tigran G. Gevorkian3

1 Botkin City Clinical Hospital, Moscow, Russia;
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
3 Blokhin National Medical Research Center of Oncology, Moscow, Russia;
4 Tsyba Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Obninsk, Russia;
5 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
6 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
7 Academy of Postgraduate Education, Moscow, Russia;
8 National Medical Research Center of Hematology, Moscow, Russia